Charles River Forms Preclinical Pacts with Target Health and Theorem

By Zachary Brennan

- Last updated on GMT

Related tags: Charles river, Chemical compound, Molecule, Chemistry

CRL Preclinical Pacts with Target Health and Theorem
CRL Preclinical Pacts with Target Health and Theorem
Charles River Laboratories has partnered with eCRO Target Health and Theorem Clinical Research to support the transfer and validation of assays supporting the CROs’ preclinical programs.

The partnerships are both similar and non-exclusive, Alan Bartlett, executive director​ of laboratory services in​ North America at Charles River, told Outsourcing-Pharma.com. He said Charles River decided to select Target and Theorem after winnowing down a larger pool of possible companies to work with.

Neither New York-based Target nor Pennsylvania-based Theorem has its own lab sciences group so Charles River is looking to fill their gaps in the areas of bioanalysis, immunogenicity and immunology so they can make a “seamless transition from nonclinical to clinical,”​ Bartlett said.

The deals will be supported by proprietary assays for large and small molecules, so for each study the companies will provide a compound’s details and then Charles River will develop the assay, sometimes from scratch, and then move through validation, Bartlett added.

Noting the downturn in preclinical studies​ over the previous three or four years, Bartlett said Charles River is seeing an upswing, especially “on the large molecule side​.”

He also said that Charles River was only looking for two new partnerships in this case but will consider other partnerships moving forward.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars